NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Ability Biotherapeutics

Ability Biotherapeutics

Private
MontrealHealthcare & Life Scienceshttps://www.ability.bio/

Last Round

Seed

Jun 18, 2024

Total Funding Raised

$30M

Company Overview

Ability Biotherapeutics is a biotechnology company that develops logic-gated antibody therapeutics for cancer and autoimmune diseases using its proprietary AI-powered discovery platform, AbiLeap™.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

antibody discoverylogic-gated antibodiesgenerative AIbiotech drug discoveryAI-driven drug discoveryimmunotherapyprecision medicinein silico drug designbiotherapeuticsoncologyautoimmune diseasedrug developmentpharma licensingcomputational biologyAI-first biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ability Biotherapeutics Comps

Public and private peers based on sector, stage, and business model.

Ability Biotherapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Ability Biotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJun 18, 2024
SeedDec 6, 2023

Key People

Founding team and executive leadership

Bharat Srinivasa

Founding CEO And Board Observer

Founding Team

Giles Day

Chief Executive Officer

Executive Team

Patrick Tremblay

Chief Operating Officer

Executive Team

Ability Biotherapeutics Investors

Notable investors and investment history

Ability Biotherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ability Biotherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ability Biotherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersMontreal
Employee Range25
Year Founded2023
Last FundingJun 18, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.